PAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership Highlights
News provided by
Share this article
Share this article
SANDUSKY, Ohio, May 6, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today highlighted that the upcoming CBD Nutraceutical Sales Rollout Presentation scheduled for tomorrow, Friday, May 7, 2021, will feature the roles Alkame Holdings, Inc. (USOTC: ALKM) and North American Cannabis Holdings, Inc. (USOTC: USMJ) play in the CBD Nutraceutical Rollout.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT .
PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PAO Group, Inc.: PAOG CBD Nutraceuticals to Hit Market This Year
Sandusky, Ohio (Newsfile Corp. - May 4, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the Company s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
PAOG is working with
Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval.
PURA Issues Farmersville Hemp Brand Update Discussing PAOG, ALKM and USMJ Partnerships Including Pharmaceutical, Cryptocurrency And Equity Initiatives
News provided by
Share this article
Share this article
DALLAS, April 20, 2021 /PRNewswire/ Puration, Inc. (USOTC: PURA) today released a management update in conjunction with the recent publication of its FY2021 Annual Report.
PURA entered the cannabis sector in 2015 with the acquisition of a license to extract CBD and THC, among other cannabinoids, from cannabis to include hemp via a U.S. Patented Cannabis Extraction Process.
After experimenting with the business model, PURA introduced EVERx CBD Sports Water and has enjoyed a good deal of success with the sales of EVERx.
PAO Group, Inc.: PAOG Announces Opportunity To Expand CBD Pharmaceutical Research
Sandusky, Ohio (Newsfile Corp. - April 13, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released a management update on the company s ongoing CBD Pharmaceutical Development Program.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
Since the acquisition, PAOG engaged Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval. PAOG reports Veristat is making substantial progress in validating and supplementing the underlying research behind RespRx.